Aviragen Therapeutics (AVIR) Misses Q4 EPS by 13c
Tweet
Share
E-mailGet Alerts AVIR Hot Sheet
Join SI Premium – FREE
Aviragen Therapeutics (NASDAQ: AVIR) reported Q4 EPS of ($0.57), $0.13 worse than the analyst estimate of ($0.44).
For earnings history and earnings-related data on Aviragen Therapeutics (AVIR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Momo (MOMO) Tops Q2 EPS by 8c; offers guidance
- Jefferies Starts Uranium Energy Corp (UEC) at Hold
- BNP Paribas Exane Starts Power Grid Corp of India Ltd (PWGR:IN) at Outperform
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
